TEM vs DHR
diagnostics · Danaher
| TEM diagnostics Healthcare | DHR Danaher Healthcare | |
|---|---|---|
| Market | ||
| Price | $80.92 +3.11% | $231.30 +1.46% |
| Market cap | $13.2B | $161.4B |
| P/E (TTM) | — | 37.3 |
| Dividend yield | — | 0.49% |
| 52-week range | $40.77 – $91.83 | $160.93 – $242.80 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Tempus Grew Revenue 23%, But A $42.8 Million Securities Gain Helped The Loss Nov 3, 2026 | Danaher (DHR): Core Sales Up 3% And Adjusted EPS Up 11.5%, But A Tax Swing Was 81% Of The… Nov 1, 2026 |
| Latest earnings | ||
| Reported | — | Oct 21, 2026 |
| Revenue | — | $6.6 billion +8.5% YoY |
| EPS | — | — |
| Guidance | — | Guidance revised |
| Revenue growth, last 4 reports | — | +8.5% |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Shared topics: Margins
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.